Based on these studies, the accumulation of CD8+ TILs and depletion of FoxP3+ TILs are thought to be favorable prognostic factors in patients with NSCLC, and these findings support the idea that augmentation of the local immune response might be a promising target for new immunotherapeutic approaches [45]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.